Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. META
6. MU
7. BLZE
8. PRIM
9. ACN
10. NVDA

Go back to Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
(NYSE: PRTO) Delayed: 27.45 -0.42 (1.51%)
Previous Close $27.87    52 Week High $16.48 
Open $27.58    52 Week Low $4.90 
Day High $27.58    P/E N/A 
Day Low $27.45    EPS $0.00 
Volume 890